Ontology highlight
ABSTRACT:
SUBMITTER: Fernandez-Martinez A
PROVIDER: S-EPMC5400635 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
Fernandez-Martinez Aranzazu A Pascual Tomás T Perrone Giuseppe G Morales Serafin S de la Haba Juan J González-Rivera Milagros M Galván Patricia P Zalfa Francesca F Amato Michela M Gonzalez Lucia L Prats Miquel M Rojo Federico F Manso Luis L Paré Laia L Alonso Immaculada I Albanell Joan J Vivancos Ana A González Antonio A Matito Judit J González Sonia S Fernandez Pedro P Adamo Barbara B Muñoz Montserrat M Viladot Margarita M Font Carme C Aya Francisco F Vidal Maria M Caballero Rosalía R Carrasco Eva E Altomare Vittorio V Tonini Giuseppe G Prat Aleix A Martin Miguel M
Oncotarget 20170301 13
PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evalu ...[more]